Effect of vitamin A on intestinal mucosal injury in pediatric patients receiving hematopoietic stem cell transplantation and chemotherapy: a quasai-randomized trial.
Ploy PattanakitsakulNalinee ChongviriyaphanSamart PakakasamaNopporn ApiwattanakulPublished in: BMC research notes (2020)
We performed a quasi-randomized trial in 30 pediatric patients undergoing HSCT. Half (n = 15) of the patients received a single high dose of vitamin A (200,000 IU) before the conditioning regimen was given, and half (n = 15) did not. Clinical data of patients who developed post-transplant complications were recorded for 60 days after HSCT. There were no significant differences in mean plasma citrulline levels on day 7 after HSCT between the treatment and control groups (5.8 vs. 5.9 µmol/L, respectively). The incidence of mucositis and other complications were not different between the two groups within 60 days of HSCT. Vitamin A supplementation prior to HSCT in pediatric patients had no clinical benefit in protecting GI mucosal integrity.
Keyphrases
- hematopoietic stem cell
- high dose
- patients undergoing
- risk factors
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- ulcerative colitis
- peritoneal dialysis
- prognostic factors
- stem cell transplantation
- electronic health record
- squamous cell carcinoma
- machine learning
- combination therapy
- chemotherapy induced
- replacement therapy
- solid state